Drugs for Hypolipoproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 205)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
2 |
|
Linagliptin |
Approved |
Phase 4 |
|
668270-12-0 |
57389748 10096344 |
Synonyms:
(R)-8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-YNYL-3-METHYL-1-(4-METHYLQUINAZOLIN-2-YLMETHYL)-3,7-DIHYDRO-PURINE-2,6-DIONE
BI 1356
BI-1356
BI-1356|Tradjenta®
BI-1356BS
BI-1356-BS
|
BS-1356-BS
LINAGLIPTIN
Linagliptina
TRADJENTA
TRAJENTA
|
|
3 |
|
Dapagliflozin |
Approved |
Phase 4 |
|
461432-26-8 |
9887712 |
Synonyms:
(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BMS-512148
BMS-512148|Farxiga®|Forxiga®
BMS-512148-05
|
Dapagliflozin
Dapagliflozina
FARXIGA
FORXIGA
|
|
4 |
|
Lixisenatide |
Approved |
Phase 4 |
|
320367-13-3 |
90472060 16139342 |
Synonyms:
ADLYXIN
Adlyxin®|AVE-0010|Lyxumia®
AQVE-10010
AVE 0010
AVE 010
AVE0010
AVE-0010
AVE-010
DES-38-PROLINE-EXENDINE-4 (HELODERMA SUSPECTUM)-(1-39)-PEPTIDYLPENTA-L-LYSYL-L-LYSINAMIDE
DESPRO38EXENDIN-4(1-39)-LYS6-NH2
|
H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2
H-HIS-GLY-GLU-GLY-THR-PHE-THR-SER-ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-ILE-GLU-TRP-LEU-LYS-ASN-GLY-GLY-PRO-SER-SER-GLY-ALA-PRO-PRO-SER-LYS-LYS-LYS-LYS-LYS-LYS-NH2
Lixisenatida
LIXISENATIDE
Lixisénatide
LYXUMIA
ZP 10
ZP-10
ZP10A PEPTIDE
|
|
5 |
|
Fenofibrate |
Approved |
Phase 4 |
|
49562-28-9 |
3339 |
Synonyms:
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoate 1-methylethyl ester
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Abbott brand OF procetofen
ABT-335
ABT-335|Lipantil®|Supralip®|Tricor®
AbZ brand OF procetofen
Aliud brand OF procetofen
Ankebin
Antara
Antara micronized procetofen
Anto brand OF procetofen
Apo feno micro
Apo fenofibrate
Apo-fenofibrate
Apo-feno-micro
Apotex brand OF procetofen
AZU, fenofibrat
Azupharma brand OF procetofen
Betapharm brand OF procetofen
Bouchara brand OF procetofen
CiL
Controlip
CT Arzneimittel brand OF procetofen
CT-Arzneimittel brand OF procetofen
Debat, fénofibrate
Durafenat
Elasterate
Elasterin
Fenobeta
Fenobrate
Fenofanton
Fenofibrat abz
Fenofibrat al
Fenofibrat azu
Fenofibrat FPH
Fenofibrat heumann
Fenofibrat hexal
Fenofibrat ratiopharm
Fenofibrat stada
Fenofibrat von CT
FENOFIBRATE
Fénofibrate debat
Fénofibrate MSD
FENOFIBRATO
Fenofibrato [INN-Spanish]
Fenofibrat-ratiopharm
FENOFIBRATUM
Fenofibratum [INN-Latin]
Fenofibric acid
FENOGAL
FENOGLIDE
Fenotard
Finofibrate
Finofibric acid
FNF
Fournier brand OF procetofen
gate Brand OF procetofen
Gen fenofibrate
Gen-fenofibrate
Genpharm brand OF procetofen
GNR Pharma brand OF procetofen
GNR-Pharma brand OF procetofen
Heumann brand OF procetofen
Heumann, fenofibrat
Hexal brand OF procetofen
Hexal, fenofibrat
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionic acid
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
|
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid
Knoll brand OF procetofen
Lichtenstein brand OF procetofen
Lipanthyl
Lipantil
LIPANTIL (TN)
LIPANTIL MICRO 200
LIPANTIL MICRO 267
LIPANTIL MICRO 67
Liparison
Lipidex
Lipidil
Lipidil Micro
Lipidil Supra
Lipidil ter
Lipidil-ter
Lipifen
Lipirex
Lipoclar
Lipofen
Lipofene
Liposit
Lipsin
Livesan
Lofibra
Luxacor
Merck dura brand OF procetofen
Micronized procetofen, antara
MTW Brand OF procetofen
MTW Fenofibrat
MTW-Fenofibrat
Nolipax
Normalip
Novartis brand OF procetofen
Novo fenofibrate
Novo-fenofibrate
Novopharm brand OF procetofen
NSC-281319
Nu fenofibrate
Nu pharm brand OF procetofen
Nu-fenofibrate
Nu-pharm brand OF procetofen
Pharmascience brand OF procetofen
Phenofibrate
PMS Fenofibrate micro
PMS-Fenofibrate micro
Procetofen
Procetofen reliant brand
Procetofen, antara micronized
Procetofene
Proctofene
Protolipan
Q Pharm brand OF procetofen
Q-Pharm brand OF procetofen
Ratiopharm brand OF procetofen
Reliant brand OF procetofen
Schering plough brand OF procetofen
Schering-plough brand OF procetofen
Secalip
Sedufen
Stada, fenofibrat
Stadapharm brand OF procetofen
Supralip
SUPRALIP 160
Tricor
TRICOR (TN)
Triglide
Trilipix
United drug brand OF procetofen
|
|
6 |
|
Glucagon |
Approved |
Phase 4 |
|
16941-32-5 |
16133228 16186314 |
Synonyms:
[<sup>125</sup>I]-glucagon
GCG(53-81)
GLUCAGEN HYPOKIT
GLUCAGON
Glucagon (recombinant dna origin)
GLUCAGON EMERGENCY KIT
|
GLUCAGON RECOMBINANT
Glucagon, human
Glucagon, porcine
GLUCAGONE
GLUCAGONUM
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
|
7 |
|
Methyltestosterone |
Approved |
Phase 4 |
|
58-18-4 |
6010 |
Synonyms:
17 alpha Methyltestosterone
17 beta Hydroxy 17 methyl 4 androsten 3 one
17 beta Methyltestosterone
17 beta-Hydroxy-17-methyl-4-androsten-3-one
17 beta-Methyltestosterone
17 Epimethyltestosterone
17(a)-Methyl-delta(4)-androsten-17(b)-ol-3-one
17(a)-Methyl-δ(4)-androsten-17(b)-ol-3-one
17(alpha)-Methyl-Delta(4)-androsten-17(beta)-ol-3-one
17(Α)-methyl-δ(4)-androsten-17(β)-ol-3-one
17alpha Methyl testosterone
17alpha Methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-Delta(4)-androsten-17beta-ol-3-one
17alpha-Methyl-delta-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-Methyl-testosterone
17-alpha-Methyltestosterone
17a-Methyl-3-oxo-4-androsten-17b-ol
17a-Methyl-delta(4)-androsten-17b-ol-3-one
17a-Methyltestosterone
17a-Methyl-δ(4)-androsten-17b-ol-3-one
17beta Hydroxy 17 methyl 4 androsten 3 one
17beta Methyltestosterone
17beta-Hydroxy-17-methyl-4-androsten-3-one
17beta-Hydroxy-17-methylandrost-4-en-3-one
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17beta-Methyltestosterone
17b-Hydroxy-17-methylandrost-4-en-3-one
17-b-Hydroxy-17-methylandrost-4-en-3-one
17-Epimethyltestosterone
17-Methyltestosterone
17Α-methyl-3-oxo-4-androsten-17β-ol
17Α-methyltestosterone
17Α-methyl-δ(4)-androsten-17β-ol-3-one
17Α-METHYL-Δ4-ANDROSTEN-17Β-OL-3-ONE
17Β-hydroxy-17-methylandrost-4-en-3-one
17-Β-hydroxy-17-methylandrost-4-en-3-one
4-Androstene-17alpha-methyl-17beta-ol-3-one
4-Androstene-17a-methyl-17b-ol-3-one
|
4-Androstene-17α-methyl-17β-ol-3-one
Android
Android (methyltestoterone)
Android 10
Android 25
Android 5
Android-10
Android-25
Android-5
CDB-110
Global pharmaceutical brand OF methyltestosterone
ICN brand 1 OF methyltestosterone
ICN brand 2 OF methyltestosterone
L 589.372
L-589.372
L-589372
Mesteron
Mesterone
Metandren
Methitest
Methyltestosterone
METHYLTESTOSTERONE CIII
Methyltestosteronum
Metiltestosterona
NSC-139965
NSC-9701
Oreton
ORETON METHYL
PERANDREN
PLEX HORMONE
POTENSAN FTE
RU 24400
RU-24400
Schering brand OF methyltestosterone
Star brand OF methyltestosterone
Testoviron
TESTOVIS
Testred
U-2842
Virilon
|
|
8 |
|
Testosterone undecanoate |
Approved, Investigational |
Phase 4 |
|
5949-44-0 |
21873174 65157 |
Synonyms:
2,15-Dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl undecanoic acid
ANDRIOL
AVEED
JATENZO
MK-3033
NEBIDO
ORG-538
RESTANDOL
|
RESTANDOL TESTOCAP
Testosterone undecanoate
Testosterone undecanoic acid
Testosterone undeconate
Testosterone undecylate
TSX-011
UNDESTOR
|
|
9 |
|
Testosterone enanthate |
Approved |
Phase 4 |
|
315-37-7 |
9416 |
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
17beta-Hydroxyandrost-4-en-3-one heptanoate
17beta-Hydroxyandrost-4-en-3-one heptanoic acid
17b-Hydroxyandrost-4-en-3-one heptanoate
17b-Hydroxyandrost-4-en-3-one heptanoic acid
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17Β-hydroxyandrost-4-en-3-one heptanoate
17Β-hydroxyandrost-4-en-3-one heptanoic acid
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn l.a.
Andropository
Androtardyl
Atlatest
BTG Brand OF testosterone enanthate
DEA no. 4000
Delatest
Delatestryl
DePatestrye
depo-testro Med
Ditate
Durathate
eifelfango Brand OF testosterone enanthate
Everone
Exten test
Jenapharm brand OF testosterone enanthate
Malogen l.a.
Malogen l.a.200
NSC-17591
Orquisteron-e
Pasadena brand OF testosterone enanthate
Primoteston depot
|
Primotestone
reposo TMD
Roberts brand OF testosterone enanthate
Rotexmedica brand OF testosterone enanthate
Rugby brand OF testosterone enanthate
Schering brand OF testosterone enanthate
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosteron depot-rotexmedica
Testosteron-depot eifelfango
Testosteron-depot jenapharm
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone 17-enanthate
Testosterone 17-enanthic acid
Testosterone enantate
Testosterone enanthate
TESTOSTERONE ENANTHATE CIII
Testosterone enanthic acid
Testosterone heptanoate
Testosterone heptanoic acid
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
Testrin p.a.
Theramed brand OF testosterone enanthate
Theramex
XYOSTED (AUTOINJECTOR)
|
|
10 |
|
Testosterone |
Approved, Investigational |
Phase 4 |
|
58-22-0 |
5408 6013 |
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Β-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Β-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
11 |
|
Acarbose |
Approved, Investigational |
Phase 4 |
|
56180-94-0 |
441184 444254 |
Synonyms:
Acarbosa
Acarbose
Acarbosum
Bay g 5421
Bayer brand OF acarbose
BAY-G 5421
BAY-G 5421|BAY-G-5421|Glucobay®|Precose®
|
BAY-G-5421
Glucobay
Glucor
Glumida
Lasa brand OF acarbose
Prandase
Precose
|
|
12 |
|
Probucol |
Approved, Investigational |
Phase 4 |
|
23288-49-5 |
4912 |
Synonyms:
4,4'- (ISOPROPYLIDENEDITHIO)BIS(2,6-DI-TERT-BUTYLPHENOL)
4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Almirall brand OF probucol
Aventis brand OF probucol
Biphenabid
Bisbid
Bisphenabid
DH-581
|
DH-581|Lorelco®
Hoechst brand OF probucol
Lesterol
Lorelco
Lurselle
NSC-652160
NSC-86225
Panavir
PROBUCOL
Probucolum
Serterol
SINLESTAL
Superlipid
|
|
13 |
|
Orange |
Approved |
Phase 4 |
|
|
|
14 |
|
Atorvastatin |
Approved |
Phase 4 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
15 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
16 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
17 |
|
Nicotinamide |
Approved, Investigational |
Phase 4 |
|
98-92-0 |
936 |
Synonyms:
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
Acid amide
Amid kyseliny nikotinove
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Austrovit PP
b 3, Vitamin
b3, Vitamin
Benicot
beta-Pyridinecarboxamide
b-Pyridinecarboxamide
Delonin amide
Dipegyl
Dipigyl
Endobion
Enduramide
Factor PP
FREEDERM
Hansamid
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm, nicotinsäureamid
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
NAM
Nandervit-N
Niacevit
Niacin
Niacinamide
Niacinamide astra brand
Niacinamide jenapharm brand
Niacinamide merck brand
Niacinamide pharmagenix brand
Niamide
NIATIN
Niavit PP
NICAM
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
|
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamide
Nicotinamidum
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Niocinamide
Niozymin
NSC-13128
NSC-27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
PP-Faktor
Propamine a
PYRIDINE-3-CARBOXAMIDE
Pyridine-3-carboxylic acid amide
Savacotyl
Vi-nicotyl
Vi-noctyl
Vitamin b 3
Vitamin b3
Vitamin PP
Witamina PP
Β-pyridinecarboxamide
|
|
18 |
|
Ezetimibe |
Approved |
Phase 4 |
|
163222-33-1 |
150311 |
Synonyms:
(1-(4-Fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
ABSORCOL
Ezedoc
Ezetimib
Ezetimiba
EZETIMIBE
ézétimibe
|
Ezetimibum
Ezetrol
MK0653
SCH 58235
SCH 58235|SCH-58235|Zetia®
SCH-58235
Zetia
|
|
19 |
|
Simvastatin |
Approved |
Phase 4 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
20 |
|
Glimepiride |
Approved |
Phase 4 |
|
93479-97-1 |
3476 |
Synonyms:
1-(4-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrrolinecarboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidate
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidate
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidic acid
Amarel
Amaryl
Avaglim
Aventis behring brand OF glimepiride
Aventis brand OF glimepiride
Aventis pharma brand OF glimepiride
Endial
Glimepirid
Glimepirida
GLIMEPIRIDE
|
Glimépiride
Glimepiridum
Glimepride
Glymepiride
HOE 490
HOE-490
Hoechst brand OF glimepiride
Lacer brand OF glimepiride
NIDDARYL
Novo-glimepiride
PMS-glimepiride
Ratio-glimepiride
Roname
Sandoz glimepiride
|
|
21 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
22 |
|
Niacin |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
59-67-6 |
938 |
Synonyms:
[<sup>3</sup>H]-nicotinic acid
3 Pyridinecarboxylic acid
3-CARBOXYLPYRIDINE
3-CARBOXYPYRIDINE
3-PICOLINIC ACID
3-PYRIDINECARBOXYLATE
3-PYRIDINECARBOXYLIC ACID
3-PYRIDYLCARBOXYLATE
3-PYRIDYLCARBOXYLIC ACID
ACIDE NICOTINIQUE
ACIDO NICOTINICO
ácido nicotínico
ACIDUM NICOTINICUM
AKOTIN
Aluminum salt, niacin
ANTI-PELLAGRA VITAMIN
APELAGRIN
beta-Pyridinecarboxylate
BETA-PYRIDINECARBOXYLIC ACID
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
DASKIL
EFACIN
ENDURACIN
Hydrochloride, niacin
INDURACIN
LINIC
Lithium nicotinate
m-Pyridinecarboxylate
M-PYRIDINECARBOXYLIC ACID
NIAC
NIACIN
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
NIACIN TD
Niacin tosylate
Niacin zinc salt
niacin|nicotinate|vitamin B<sub>3</sub>|vitamin PP
Niacina
NIACINE
|
NIACOR
NIASPAN
NIASPAN ER
NIASPAN TITRATION STARTER PACK
NICACID
NICAMIN
NICANGIN
Nico 400
Nico400
Nico-400
NICOBID
NICOCAP
NICODELMINE
NICOLAR
NICONACID
NICOSAN 3
NICO-SPAN
NICOTINATE
Nicotinate, lithium
NICOTINIC ACID
NICOTINIPCA
NICYL
NIKOTINSAEURE
Nikotinsäure
NSC-169454
NYCLIN
P.P. FACTOR
PELLAGRA PREVENTIVE FACTOR
PELLAGRIN
PELONIN
PEVITON
Potassium salt, niacin
PP FACTOR
PYRIDINE-3-CARBOXYLIC ACID
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
PYRIDINE-BETA-CARBOXYLIC ACID
Pyridine-β-carboxylate
PYRIDINE-Β-CARBOXYLIC ACID
SIMCOR
SLO-NIACIN
Sodium salt, niacin
Tartrate, niacin
TINIC
Tosylate, niacin
VITAMIN B3
VITAMIN PP
WAMPOCAP
Β-pyridinecarboxylate
Β-PYRIDINECARBOXYLIC ACID
|
|
23 |
|
Anagliptin |
Investigational |
Phase 4 |
|
739366-20-2 |
67068474 44513473 |
Synonyms:
ANAGLIPTIN
compound 4a [PMID: 22019046]|CWP-403|SK-0403|SK0403|Suiny®
|
|
|
24 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
25 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
26 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
27 |
|
Protective Agents |
|
Phase 4 |
|
|
|
28 |
|
Glucagon-Like Peptide 1 |
|
Phase 4 |
|
|
|
29 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
30 |
|
Antioxidants |
|
Phase 4 |
|
|
|
31 |
|
Rosuvastatin Calcium |
|
Phase 4 |
|
147098-20-2 |
|
Synonyms:
CRESTOR
EZALLOR
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM SALT
|
S-4522
ZD-4522
ZD-4522 (CALCIUM SALT)
|
|
32 |
|
Phytosterol |
|
Phase 4 |
|
|
|
33 |
|
Androgens |
|
Phase 4 |
|
|
|
34 |
|
Testosterone 17 beta-cypionate |
|
Phase 4 |
|
|
|
35 |
|
Chrysarobin |
|
Phase 4 |
|
|
|
36 |
|
Cardiac Glycosides |
|
Phase 4 |
|
|
|
37 |
|
Glycoside Hydrolase Inhibitors |
|
Phase 4 |
|
|
|
38 |
|
Colesevelam Hydrochloride |
|
Phase 4 |
|
|
|
39 |
|
Anabolic Agents |
|
Phase 4 |
|
|
|
40 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
41 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
42 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
43 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
44 |
|
Vitamins |
|
Phase 4 |
|
|
|
45 |
|
Folate |
|
Phase 4 |
|
|
|
46 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
47 |
|
Vitamin B3 |
|
Phase 4 |
|
|
|
48 |
|
Trace Elements |
|
Phase 4 |
|
|
|
49 |
|
Nicotinic Acids |
|
Phase 4 |
|
|
|
50 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 278)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes |
Unknown status |
NCT02721888 |
Phase 4 |
Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) |
2 |
Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients |
Unknown status |
NCT02280174 |
Phase 4 |
linagliptin |
3 |
Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein |
Unknown status |
NCT00736463 |
Phase 4 |
Simvastatin;Atorvastatin 80 mg |
4 |
A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes |
Unknown status |
NCT02077257 |
Phase 4 |
Rosuvastatin |
5 |
Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes |
Unknown status |
NCT03269058 |
Phase 4 |
Dapagliflozin;Placebos |
6 |
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) |
Unknown status |
NCT02501850 |
Phase 4 |
Liraglutide;metformin |
7 |
Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects |
Unknown status |
NCT01301794 |
Phase 4 |
|
8 |
Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function |
Completed |
NCT00298909 |
Phase 4 |
niaspan (extended-release niacin);niacin |
9 |
Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration. |
Completed |
NCT01321034 |
Phase 4 |
Niacin/Laropiprant |
10 |
A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study) |
Completed |
NCT00645151 |
Phase 4 |
Atorvastatin |
11 |
Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome |
Completed |
NCT00841217 |
Phase 4 |
GW501516;placebo pill |
12 |
Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome |
Completed |
NCT00632840 |
Phase 4 |
Atorvastatin and fenofibrate |
13 |
Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism |
Completed |
NCT02111434 |
Phase 4 |
Testosterone |
14 |
ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. |
Completed |
NCT00442325 |
Phase 4 |
Atorvastatin (Lipitor) |
15 |
12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients |
Completed |
NCT00747149 |
Phase 4 |
Rosuvastatin |
16 |
ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg |
Completed |
NCT00442845 |
Phase 4 |
Atorvastatin (Lipitor) |
17 |
Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial |
Completed |
NCT02330406 |
Phase 4 |
Anagliptin;Sitagliptin |
18 |
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients |
Completed |
NCT02355509 |
Phase 4 |
Acarbose;Placebo |
19 |
THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA |
Completed |
NCT00932620 |
Phase 4 |
SIMVASTATIN 40 mg;SIMVASTATIN/EZETIMIBE 10/10 mg |
20 |
Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol |
Completed |
NCT01122355 |
Phase 4 |
lipid modification |
21 |
Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology |
Completed |
NCT00307307 |
Phase 4 |
Niacin/simvastatin compared to simvastatin alone at 2 doses |
22 |
Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy |
Completed |
NCT00276133 |
Phase 4 |
Effects of atorvastatin versus probucol on small dense LDL |
23 |
Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy. |
Completed |
NCT00249938 |
Phase 4 |
Minute Maid Heart Wise orange juice;Welchol |
24 |
The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes |
Completed |
NCT00931879 |
Phase 4 |
omega-3-ethyl esters;Placebo |
25 |
Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. |
Completed |
NCT01454011 |
Phase 4 |
Testosteron 250mg injection;Testosterone 50mg transdermal application |
26 |
The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes |
Completed |
NCT01384058 |
Phase 4 |
ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20 |
27 |
Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes |
Completed |
NCT02185963 |
Phase 4 |
Rosuvastatin |
28 |
Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood |
Completed |
NCT02839902 |
Phase 4 |
TAK-085 |
29 |
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon |
Completed |
NCT01155206 |
Phase 4 |
glucagon |
30 |
Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial |
Active, not recruiting |
NCT02579499 |
Phase 4 |
fixed high potent statin therapy;targeted LDL-C goal statin |
31 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes |
Terminated |
NCT00651014 |
Phase 4 |
Ezetimibe;Placebo |
32 |
Effect of Sitagliptin on Postprandial Lipoprotein Metabolism |
Terminated |
NCT00939939 |
Phase 4 |
sitagliptin;glimepiride |
33 |
A Pilot Study Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia in Clinical Routine |
Terminated |
NCT03559309 |
Phase 4 |
|
34 |
Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia |
Terminated |
NCT01239992 |
Phase 4 |
Niacin/ Laropiprant |
35 |
An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia |
Withdrawn |
NCT02069106 |
Phase 4 |
|
36 |
A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X |
Unknown status |
NCT01109498 |
Phase 2, Phase 3 |
Mycophenolate mofetil;cyclosporine |
37 |
Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study) |
Unknown status |
NCT00633698 |
Phase 3 |
Nicotinic acid (niacin);Placebo |
38 |
Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) |
Unknown status |
NCT01286909 |
Phase 3 |
|
39 |
ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) |
Completed |
NCT02658175 |
Phase 3 |
Volanesorsen |
40 |
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects |
Completed |
NCT00891306 |
Phase 2, Phase 3 |
mycophenolate mofetil;cyclosporine;methylprednisolone |
41 |
Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C |
Completed |
NCT01562080 |
Phase 2, Phase 3 |
|
42 |
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like |
Completed |
NCT01958775 |
Phase 3 |
GLP-2;Placebo |
43 |
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes |
Completed |
NCT00660075 |
Phase 3 |
Sitagliptin;Placebo |
44 |
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment |
Completed |
NCT02585895 |
Phase 3 |
|
45 |
A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level. |
Completed |
NCT02133807 |
Phase 3 |
|
46 |
A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c) |
Completed |
NCT00551447 |
Phase 3 |
MK0653, ezetimibe / Duration of Treatment: 27 Weeks;MK0733, simvastatin / Duration of Treatment: 27 Weeks;Comparator: simvastatin / Duration of Treatment: 27 Weeks |
47 |
Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity |
Completed |
NCT00438061 |
Phase 3 |
|
48 |
Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial |
Completed |
NCT02116517 |
Phase 3 |
|
49 |
Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity |
Completed |
NCT00392717 |
Phase 3 |
Atorvastatin;Fish oils |
50 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease. |
Completed |
NCT00092638 |
Phase 3 |
MK0653, ezetimibe;Comparator: ezetimibe, placebo |
|